VANCOUVER, British Columbia–(Organization WIRE)– Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Enterprise”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an proof-primarily based mental healthcare organization focused on the improvement and implementation of revolutionary clinical options, like psychedelic medicine and digital therapeutics as supported by clinical investigation, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), now announced that the Enterprise has completed the CMC package to be utilised in assistance of a phase 2A microdose psilocybin fragile X syndrome clinical trial for its client Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Client”).

Nova has developed 1.five mg psilocybin microdose capsules. These capsules have been developed according to defined manufacturing processes and solution specifications as outlined in chemistry, manufacturing, and controls (CMC) published recommendations.

The package to be submitted to Overall health Canada for approval contains:

– Phase two manufacturing approach file for psilocybin active pharmaceutical ingredient (API).
– Completed solution batch manufacturing records that confirms final capsule batch has been developed.
– Psilocybin capsule dissolution parameters that meet regulatory specifications.

“This is undoubtedly an fascinating time for KGK Science and our Client as we finalize the clinical trial application that will be submitted to Overall health Canada for approval of a Phase 2A study evaluation psilocybin microdose therapy for fragile X syndrome, the top lead to of autism spectrum disorder (ASD),” commented Najla Guthrie, CEO of Wellbeing Digital &amp KGK Science.

“KGK is a top contract investigation organization (CRO), supplying higher-top quality clinical investigation trials and specialist regulatory assistance. We are pleased to be functioning with the Enterprise in this venture. Additionally, NOVA is excited to initiate the availability of its 1.five mg psilocybin capsules to physicians, clinics and pharmaceutical firms in Canada for its possible therapeutic use in non-ASD clinical trials, like but not restricted to diabetes, heart illness, epileptic circumstances and post-traumatic tension disorder (PTSD),” added Will Rascan, President &amp CEO of Nova Mentis.


Subsidiary of Wellbeing Digital Sciences, KGK is a top North American contract investigation organization primarily based in London, Ontario that mainly delivers higher-top quality clinical investigation trials with a concentrate on nutraceutical and emerging well being care goods. Founded in 1997, the organization has effectively helped hundreds of firms with custom made clinical trials and claim substantiation techniques to move goods into worldwide markets. KGK’s other current service lines incorporate specialist regulatory assistance and compliance options, participant recruitment, investigation assistance solutions and consulting solutions. Additionally, the organization has developed more than 150 publications, executed more than 400 clinical trials across additional than 40 indications, amassed 25,000 participants in its database and collected ten million information points. For further facts, please stop by


Wellbeing Digital Sciences Inc. is an proof-primarily based mental healthcare organization focused on the improvement and implementation of revolutionary clinical therapy options, like psychedelic medicine and digital therapeutics, as supported by clinical investigation. Its mission is supported by a network of North American clinics that offer forward-considering therapies and other sorts of therapy to sufferers as nicely as via a contract investigation organization that delivers clinical trials solutions to customers pursuing drug improvement. For further facts, please stop by


Nova Mentis Life Science Corp. is a Canadian-primarily based biotechnology organization and worldwide leader in establishing diagnostics and psilocybin-primarily based therapeutics for neuroinflammatory issues. Nova is the initial biotech organization to obtain orphan drug designation in each the United States and European Union for the use of psilocybin in the therapy of Fragile X Syndrome (FXS). Our purpose is to diagnose and treat debilitating chronic circumstances that have unmet healthcare wants, such as autism spectrum disorder (ASD) and FXS. For additional facts on the Enterprise, please stop by or e-mail

On behalf of:
Najla Guthrie
Chief Executive Officer

Notice With regards to Forward-Hunting Info:

This news release includes forward-searching statements like but not restricted to statements concerning the Company’s organization, assets or investments, as nicely other statements that are not historical details. Readers are cautioned not to location undue reliance on forward-searching statements, as there can be no assurance that the plans, intentions or expectations upon which they are primarily based will take place. By their nature, forward-searching statements involve many assumptions, identified and unknown dangers and uncertainties, each common and certain, that contribute to the possibility that the predictions, forecasts, projections and other forward-searching statements will not take place, which may possibly lead to actual functionality and outcomes in future periods to differ materially from any estimates or projections of future functionality or outcomes expressed or implied by such forward-searching statements. These assumptions, dangers and uncertainties incorporate, amongst other items, the state of the economy in common and capital markets in certain, investor interest in the organization and prospects of the Enterprise.

The forward-searching statements contained in this news release are created as of the date of this news release. Except as expected by law, the Enterprise disclaims any intention and assumes no obligation to update or revise any forward-searching statements, no matter if as a outcome of new facts, future events or otherwise, except as expected by applicable securities law. Moreover, the Enterprise undertakes no obligation to comment on the expectations of, or statements created, by third parties in respect of the matters discussed above.

By Editor

Leave a Reply